TheraSphere is a well-tolerated and clinically proven locoregional treatment (LRT) to treat hepatocellular carcinoma (HCC) and has been shown to elicit an immune response.1,2
Y-90 shapes the microenvironment of HCC tumors by inducing tumor cell death and T cell recruitment and activation following therapy.1
TheraSphere targets the tumor while minimizing impact to surrounding healthy tissue. It safely delivers high-dose radiation directly to the tumor, yielding strong local tumor control. TheraSphere is well-tolerated with minimal side-effects, demonstrating long-term preservation of health-related quality of life (HRQoL).3
In the LEGACY study, 0% of patients experienced radiation induced liver disease or failure.3
Patients treated with TheraSphere were able to maintain adequate hepatic function for a measurable amount of time to allow for initiation of systemics.4
TheraSphere preserves eligibility for future treatment options.5
The ROWAN study is a global, open-label, multi-center, phase II, single-arm study to assess the efficacy of TheraSphere Y-90 Glass Microspheres followed by Durvalumab with Tremelimumab (STRIDE regimen) in patients with hepatocellular carcinoma. ROWAN will explore if there is a benefit of TheraSphere with immunotherapy to improve response for HCC patients.
With $30+M invested globally, Boston Scientific is actively supporting studies assessing the safety and efficacy of TheraSphere in combination with systemic therapies.
HCC stage focus
Drug classification targets
Boston Scientific is supporting studies across multiple stages and drug classification targets.
References
TheraSphere is a registered trademark of Theragenics Corporation used under license by Boston Scientific Medical Device Limited, a wholly owned indirect subsidiary of Boston Scientific Corporation.
